Neutrophil to lymphocyte ratio (NLR) improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents

A. Romano, N. L. Parrinello, M. L. Consoli, L. Marchionni, S. Forte, C. Conticello, A. Pompa, A. Corso, G. Milone, F. Di Raimondo, I. Borrello

Research output: Contribution to journalArticle

Abstract

Recent reports identify the ratio between absolute neutrophil count (ANC) and absolute lymphocyte count (ALC), called neutrophil to lymphocyte ratio (NLR), as a predictor of progression-free survival (PFS) and overall survival (OS) in various malignancies. We retrospectively examined the NLR in a cohort of 309 newly diagnosed multiple myeloma (MM) patients treated upfront with novel agents. NLR was calculated using data obtained from the complete blood count (CBC) at diagnosis and subsequently correlated with PFS and OS. The median NLR was 1.9 (range 0.4–15.9). Higher NLR was independent of international staging system (ISS) stage, plasma cell infiltration or cytogenetics. The 5-year PFS and OS estimates were, respectively, 18.2 and 36.4 % for patients with NLR ≥ 2 versus 25.5 and 66.6 % in patients with NLR <2. Among younger patients (age

Original languageEnglish
Pages (from-to)1875-1883
Number of pages9
JournalAnnals of Hematology
Volume94
Issue number11
DOIs
Publication statusPublished - Nov 22 2015

Fingerprint

Multiple Myeloma
Neutrophils
Lymphocytes
Disease-Free Survival
Survival
Blood Cell Count
Lymphocyte Count
Plasma Cells
Cytogenetics
Neoplasms

Keywords

  • Granulocyte
  • ISS
  • Lymphocyte
  • Multiple myeloma

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

Cite this

Romano, A., Parrinello, N. L., Consoli, M. L., Marchionni, L., Forte, S., Conticello, C., ... Borrello, I. (2015). Neutrophil to lymphocyte ratio (NLR) improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents. Annals of Hematology, 94(11), 1875-1883. https://doi.org/10.1007/s00277-015-2462-4

Neutrophil to lymphocyte ratio (NLR) improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents. / Romano, A.; Parrinello, N. L.; Consoli, M. L.; Marchionni, L.; Forte, S.; Conticello, C.; Pompa, A.; Corso, A.; Milone, G.; Di Raimondo, F.; Borrello, I.

In: Annals of Hematology, Vol. 94, No. 11, 22.11.2015, p. 1875-1883.

Research output: Contribution to journalArticle

Romano, A, Parrinello, NL, Consoli, ML, Marchionni, L, Forte, S, Conticello, C, Pompa, A, Corso, A, Milone, G, Di Raimondo, F & Borrello, I 2015, 'Neutrophil to lymphocyte ratio (NLR) improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents', Annals of Hematology, vol. 94, no. 11, pp. 1875-1883. https://doi.org/10.1007/s00277-015-2462-4
Romano, A. ; Parrinello, N. L. ; Consoli, M. L. ; Marchionni, L. ; Forte, S. ; Conticello, C. ; Pompa, A. ; Corso, A. ; Milone, G. ; Di Raimondo, F. ; Borrello, I. / Neutrophil to lymphocyte ratio (NLR) improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents. In: Annals of Hematology. 2015 ; Vol. 94, No. 11. pp. 1875-1883.
@article{808af926bc8c4ebdbce0f45b49b09e36,
title = "Neutrophil to lymphocyte ratio (NLR) improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents",
abstract = "Recent reports identify the ratio between absolute neutrophil count (ANC) and absolute lymphocyte count (ALC), called neutrophil to lymphocyte ratio (NLR), as a predictor of progression-free survival (PFS) and overall survival (OS) in various malignancies. We retrospectively examined the NLR in a cohort of 309 newly diagnosed multiple myeloma (MM) patients treated upfront with novel agents. NLR was calculated using data obtained from the complete blood count (CBC) at diagnosis and subsequently correlated with PFS and OS. The median NLR was 1.9 (range 0.4–15.9). Higher NLR was independent of international staging system (ISS) stage, plasma cell infiltration or cytogenetics. The 5-year PFS and OS estimates were, respectively, 18.2 and 36.4 {\%} for patients with NLR ≥ 2 versus 25.5 and 66.6 {\%} in patients with NLR <2. Among younger patients (age",
keywords = "Granulocyte, ISS, Lymphocyte, Multiple myeloma",
author = "A. Romano and Parrinello, {N. L.} and Consoli, {M. L.} and L. Marchionni and S. Forte and C. Conticello and A. Pompa and A. Corso and G. Milone and {Di Raimondo}, F. and I. Borrello",
year = "2015",
month = "11",
day = "22",
doi = "10.1007/s00277-015-2462-4",
language = "English",
volume = "94",
pages = "1875--1883",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "11",

}

TY - JOUR

T1 - Neutrophil to lymphocyte ratio (NLR) improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents

AU - Romano, A.

AU - Parrinello, N. L.

AU - Consoli, M. L.

AU - Marchionni, L.

AU - Forte, S.

AU - Conticello, C.

AU - Pompa, A.

AU - Corso, A.

AU - Milone, G.

AU - Di Raimondo, F.

AU - Borrello, I.

PY - 2015/11/22

Y1 - 2015/11/22

N2 - Recent reports identify the ratio between absolute neutrophil count (ANC) and absolute lymphocyte count (ALC), called neutrophil to lymphocyte ratio (NLR), as a predictor of progression-free survival (PFS) and overall survival (OS) in various malignancies. We retrospectively examined the NLR in a cohort of 309 newly diagnosed multiple myeloma (MM) patients treated upfront with novel agents. NLR was calculated using data obtained from the complete blood count (CBC) at diagnosis and subsequently correlated with PFS and OS. The median NLR was 1.9 (range 0.4–15.9). Higher NLR was independent of international staging system (ISS) stage, plasma cell infiltration or cytogenetics. The 5-year PFS and OS estimates were, respectively, 18.2 and 36.4 % for patients with NLR ≥ 2 versus 25.5 and 66.6 % in patients with NLR <2. Among younger patients (age

AB - Recent reports identify the ratio between absolute neutrophil count (ANC) and absolute lymphocyte count (ALC), called neutrophil to lymphocyte ratio (NLR), as a predictor of progression-free survival (PFS) and overall survival (OS) in various malignancies. We retrospectively examined the NLR in a cohort of 309 newly diagnosed multiple myeloma (MM) patients treated upfront with novel agents. NLR was calculated using data obtained from the complete blood count (CBC) at diagnosis and subsequently correlated with PFS and OS. The median NLR was 1.9 (range 0.4–15.9). Higher NLR was independent of international staging system (ISS) stage, plasma cell infiltration or cytogenetics. The 5-year PFS and OS estimates were, respectively, 18.2 and 36.4 % for patients with NLR ≥ 2 versus 25.5 and 66.6 % in patients with NLR <2. Among younger patients (age

KW - Granulocyte

KW - ISS

KW - Lymphocyte

KW - Multiple myeloma

UR - http://www.scopus.com/inward/record.url?scp=84941993505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941993505&partnerID=8YFLogxK

U2 - 10.1007/s00277-015-2462-4

DO - 10.1007/s00277-015-2462-4

M3 - Article

C2 - 26223359

AN - SCOPUS:84941993505

VL - 94

SP - 1875

EP - 1883

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 11

ER -